Since TNF-α is a cytokine central to the pathophysiology of IBD, and acts as a key mediator through which multiple cytokines and leukocyte trafficking are regulated, targeting TNF-α helps to interrupt the disease process rather than directly inhibiting its etiology. Here, TNF is linked to irritable bowel syndrome.